Reaction
Alveolar Osteitis reporting signals
As of the last recalculation, Alveolar Osteitis appears in 421 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS (PRR 145.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Diltiazem Hydrochloride Extended-Release Tablets | 31 | 145.3 | 145.7 |
| Mometasone | 33 | 96.4 | 96.6 |
| Alendronate Sodium | 117 | 79.0 | 79.1 |
| Theophylline Anhydrous | 13 | 53.5 | 53.5 |
| Metformin Hydrochloride Tablets | 54 | 53.3 | 53.3 |
| Metformin Hydrochloride Extended-Release Tablets | 54 | 53.3 | 53.3 |
| Metformin Hydrochloride Tablet | 54 | 53.2 | 53.3 |
| Theophylline | 12 | 53.1 | 53.2 |
| Cephalexin | 22 | 53.0 | 53.0 |
| Metformin Hydrochloride | 54 | 51.6 | 51.6 |
| Omalizumab | 72 | 50.2 | 50.2 |
| Diltiazem Hydrochloride | 32 | 49.4 | 49.5 |
| Mometasone Furoate | 35 | 45.2 | 45.2 |
| Atorvastatin Calcium, Film Coated | 43 | 33.6 | 33.7 |
| Piperacillin Sodium,Tazobactam Sodium | 15 | 29.0 | 29.0 |